Ephedrine Alkaloid AERs Nearly Double Over Two Years - AAPCC Data
This article was originally published in The Tan Sheet
Executive Summary
Adverse event reports related to ephedrine alkaloid dietary supplement use almost doubled between 1997 and 1999, according to poison control center data cited in a Sept. 5 citizen petition to FDA.
You may also be interested in...
Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman
There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1
Congressional DSHEA Amendment Potential Prompts NNFA Lobbying Activity
NNFA is initiating a lobbying effort in response to concerns Congress might amend the Dietary Supplement Health & Education Act following the recent uproar over ephedra safety
Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events